High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer

European Journal of Cancer

Volumn 49, Issue 6, 2013, Pages 1273-1279

  Flammiger, Anna ^a   Weisbach, Lars ^a   Huland, Hartwig ^a   Tennstedt, Pierre ^a   Simon, Ronald ^a   Minner, Sarah ^a   Bokemeyer, Carsten ^a   Sauter, Guido ^a   Schlomm, Thorsten ^a   Trepel, Martin ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

FOXP3; Prostate cancer; PSA recurrence free survival; Regulatory T cells; Tissue microarray

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR FOXP3;

ADULT; ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CELL DENSITY; CELL PROLIFERATION; GLEASON SCORE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REGULATORY T LYMPHOCYTE; TUMOR MICROENVIRONMENT;

AGED; ANDROGEN ANTAGONISTS; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNITY, CELLULAR; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PREOPERATIVE PERIOD; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TISSUE ARRAY ANALYSIS;

EID: 84875744038     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.11.035     Document Type: Article

References (44)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
2. W.S. Webster, E.J. Small, B.I. Rini, and E.D. Kwon Prostate cancer immunology: biology, therapeutics, and challenges J Clin Oncol 23 2005 8262 8269
3. P.W. Kantoff, C.S. Higano, and N.D. Shore Sipuleucel-T immunotherapy for castration- resistant prostate cancer N Engl J Med 363 2010 411 422
4. P. Yu, and Y.X. Fu Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest 86 2006 231 245
5. H. Nishikawa, and S. Sakaguchi Regulatory T cells in tumor immunity Int J Cancer 127 2010 759 767
6. C.M. Wilke, K. Wu, E. Zhao, G. Wang, and W. Zou Prognostic significance of regulatory T cells in tumor Int J Cancer 127 2010 748 758
7. W.L. Byrne, K.H. Mills, J.A. Lederer, and G.C. O'Sullivan Targeting regulatory T cells in cancer Cancer Res 71 2011 6915 6920
8. M. Beyer, and J.L. Schultze Regulatory T cells in cancer Blood 108 2006 804 811
9. A.M. Miller, K. Lundberg, and V. Ozenci CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients J Immunol 177 2006 7398 7405
10. K. Ebelt, G. Babaryka, and B. Frankenberger Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters Eur J Cancer 45 2009 1664 1672
11. S. Hori, T. Nomura, and S. Sakaguchi Control of regulatory T cell development by the transcription factor Foxp3 Science 299 2003 1057 1061
12. J.D. Fontenot, M.A. Gavin, and A.Y. Rudensky Foxp3 programs the development and function of CD4+CD25+ regulatory T cells Nat Immunol 4 2003 330 336
13. T. Schlomm, L. Iwers, and P. Kirstein Clinical significance of p53 alterations in surgically treated prostate cancers Mod Pathol 21 2008 1371 1378
14. S. Minner, B. Jessen, and L. Stiedenroth Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer Clin Cancer Res 16 2010 1553 1560
15. S.M. Hsu, L. Raine, and H. Fanger Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures J Histochem Cytochem 29 1981 577 580
16. M. Mercader, B.K. Bodner, and M.T. Moser T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer Proc Natl Acad Sci U S A 98 2001 14565 14570
17. P.O. Gannon, A.O. Poisson, N. Delvoye, R. Lapointe, A.M. Mes-Masson, and F. Saad Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients J Immunol Methods 348 2009 9 17
18. R.R. Berges, Y. Furuya, L. Remington, H.F. English, T. Jacks, and J.T. Isaacs Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation Proc Natl Acad Sci U S A 90 1993 8910 8914
19. N. Kyprianou, and J.T. Isaacs Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death Mol Endocrinol 3 1989 1515 1522
20. W. Chen, and J.E. Konkel TGF-beta and 'adaptive' Foxp3(+) regulatory T cells J Mol Cell Biol 2 2010 30 36
21. S. Vesalainen, P. Lipponen, M. Talja, and K. Syrjanen Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma Eur J Cancer 30A 1994 1797 1803
22. T.J. Curiel, G. Coukos, and L. Zou Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat Med 10 2004 942 949
23. S. Shimura, G. Yang, S. Ebara, T.M. Wheeler, A. Frolov, and T.C. Thompson Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression Cancer Res 60 2000 5857 5861
24. A. Fleischmann, T. Schlomm, and J. Kollermann Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis Prostate 69 2009 976 981
25. L.M. Coussens, and Z. Werb Inflammation and cancer Nature 420 2002 860 867
26. A.M. De Marzo, E.A. Platz, and S. Sutcliffe Inflammation in prostate carcinogenesis Nat Rev Cancer 7 2007 256 269
27. S.C. Kao, N. Pavlakis, and R. Harvie High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy Clin Cancer Res 16 2010 5805 5813
28. K.M. Sarraf, E. Belcher, E. Raevsky, A.G. Nicholson, P. Goldstraw, and E. Lim Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer J Thorac Cardiovasc Surg 137 2009 425 428
29. W. Chua, K.A. Charles, V.E. Baracos, and S.J. Clarke Neutrophil/ lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer Br J Cancer 104 2011 1288 1295
30. M.J. Proctor, D.S. Morrison, and D. Talwar A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow inflammation outcome study Eur J Cancer 47 2011 2633 2641
31. J. Yokokawa, V. Cereda, and C. Remondo Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer Clin Cancer Res 14 2008 1032 1040
32. S.B. Fox, R. Launchbury, and G.J. Bates The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia-inducible factor (HIF)-2alpha but not HIF-1alpha Prostate 67 2007 623 629
33. G. Roncador, P.J. Brown, and L. Maestre Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level Eur J Immunol 35 2005 1681 1691
34. B.C. Fox, P.A. Bignone, P.J. Brown, and A.H. Banham Defense of the clone: antibody 259D effectively labels human FOXP3 in a variety of applications Blood 111 2008 3897 3899
35. J. Carreras, A. Lopez-Guillermo, and B.C. Fox High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma Blood 108 2006 2957 2964
36. A. Tzankov, C. Meier, P. Hirschmann, P. Went, S.A. Pileri, and S. Dirnhofer Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma Haematologica 93 2008 193 200
37. Y. Mizukami, K. Kono, and Y. Kawaguchi Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer Br J Cancer 98 2008 148 153
38. D. Anz, S. Eiber, and C. Scholz In breast cancer, a high ratio of tumour-infiltrating intraepithelial CD8+ to FoxP3+ cells is characteristic for the medullary subtype Histopathology 59 2011 965 974
39. P.J. Mintz, J. Kim, and K.A. Do Fingerprinting the circulating repertoire of antibodies from cancer patients Nat Biotechnol 21 2003 57 63
40. C. Alberti Prostate cancer progression and surrounding microenvironment Int J Biol Markers 21 2006 88 95
41. C.G. Drake Prostate cancer as a model for tumour immunotherapy Nat Rev Immunol 10 2010 580 593
42. G. Sonpavde, G. Di Lorenzo, C.S. Higano, P.W. Kantoff, R. Madan, and N.D. Shore The Role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature Eur Urol 2011
43. E.M. Gabriel, and E.C. Lattime Anti-CTL-associated antigen 4: are regulatory T cells a target? Clin Cancer Res 13 2007 785 788
44. E.J. Small, N.S. Tchekmedyian, B.I. Rini, L. Fong, I. Lowy, and J.P. Allison A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer Clin Cancer Res 13 2007 1810 1815